Boehringer Confident on New Antiretroviral

German drug major Boehringer Ingelheim has announced positive results for its Phase III clinical trials of its prospective HIV/AIDS therapy tipranavir. According to the company, the studies indicate that the compound has a clear therapeutic lead over leading non-peptidic protease inhibitor Kaletra, marketed by US-based firm Abbott Laboratories.

Boehringer Ingelheim also claims that the product is effective against mutant strains of the virus. Notably, the company already produces Viramune (nevirapine), an earlier therapy widely distributed in AIDS pandemic areas in Sub-Saharan Africa.